KV’s SITE RELEASE® drug delivery system provides a creative, unique approach
to drug delivery, combining bioadhesion to wet living tissues with controlled release
of the drug agent. Products incorporating SITE RELEASE® technology are
designed to adhere to wet living tissues, yet are minimally affected by the presence
of moisture.
SITE RELEASE® is currently commercialized in two Ther-Rx Corporation
products, Clindesse® (clindamycin phosphate) and Gynazole-1® (butoconazole nitrate), thus providing one-dose-to-treat
products, with a potential to improve patient compliance, while also allowing anytime
dosing with minimized leakage. SITE RELEASE® butoconazole nitrate 2%
vaginal cream, used in Gyanazole-1® and clindamycin phosphate 2% vaginal
cream used in Clindesse® have both received FDA approval.
Click here to review our Technology Evaluation: Advancing Vaginal Drug Delivery
|
|
|
|